Cargando…

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)

Background: In anal cancer, there are no markers nor other laboratory indexes that can predict prognosis and guide clinical practice for patients treated with concurrent chemoradiation. In this study, we retrospectively investigated the influence of immune inflammation indicators on treatment outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Casadei-Gardini, Andrea, Montagnani, Francesco, Casadei, Chiara, Arcadipane, Francesca, Andrikou, Kalliopi, Aloi, Deborah, Prete, Alessandra Anna, Zampino, Maria Giulia, Argentiero, Antonella, Pugliese, Giuseppe, Martini, Stefania, Iorio, Giuseppe Carlo, Scartozzi, Mario, Mistrangelo, Massimiliano, Fornaro, Lorenzo, Cassoni, Paola, Marisi, Giorgia, Dell’Acqua, Veronica, Ravenda, Paola Simona, Lonardi, Sara, Silvestris, Nicola, De Bari, Berardino, Ricardi, Umberto, Cascinu, Stefano, Franco, Pierfrancesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506779/
https://www.ncbi.nlm.nih.gov/pubmed/31118786
http://dx.doi.org/10.2147/CMAR.S197349
_version_ 1783416917307949056
author Casadei-Gardini, Andrea
Montagnani, Francesco
Casadei, Chiara
Arcadipane, Francesca
Andrikou, Kalliopi
Aloi, Deborah
Prete, Alessandra Anna
Zampino, Maria Giulia
Argentiero, Antonella
Pugliese, Giuseppe
Martini, Stefania
Iorio, Giuseppe Carlo
Scartozzi, Mario
Mistrangelo, Massimiliano
Fornaro, Lorenzo
Cassoni, Paola
Marisi, Giorgia
Dell’Acqua, Veronica
Ravenda, Paola Simona
Lonardi, Sara
Silvestris, Nicola
De Bari, Berardino
Ricardi, Umberto
Cascinu, Stefano
Franco, Pierfrancesco
author_facet Casadei-Gardini, Andrea
Montagnani, Francesco
Casadei, Chiara
Arcadipane, Francesca
Andrikou, Kalliopi
Aloi, Deborah
Prete, Alessandra Anna
Zampino, Maria Giulia
Argentiero, Antonella
Pugliese, Giuseppe
Martini, Stefania
Iorio, Giuseppe Carlo
Scartozzi, Mario
Mistrangelo, Massimiliano
Fornaro, Lorenzo
Cassoni, Paola
Marisi, Giorgia
Dell’Acqua, Veronica
Ravenda, Paola Simona
Lonardi, Sara
Silvestris, Nicola
De Bari, Berardino
Ricardi, Umberto
Cascinu, Stefano
Franco, Pierfrancesco
author_sort Casadei-Gardini, Andrea
collection PubMed
description Background: In anal cancer, there are no markers nor other laboratory indexes that can predict prognosis and guide clinical practice for patients treated with concurrent chemoradiation. In this study, we retrospectively investigated the influence of immune inflammation indicators on treatment outcome of anal cancer patients undergoing concurrent chemoradiotherapy. Methods: All patients had a histologically proven diagnosis of squamous cell carcinoma of the anal canal/margin treated with chemoradiotherapy according to the Nigro’s regimen. Impact on prognosis of pre-treatment systemic index of inflammation (SII) (platelet x neutrophil/lymphocyte), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were analyzed. Results: A total of 161 consecutive patients were available for the analysis. Response to treatment was the single most important factor for progression-free survival (PFS) and overall survival (OS). At univariate analysis, higher SII level was significantly correlated to lower PFS (p<0.01) and OS (p=0.046). NLR level was significantly correlated to PFS (p=0.05), but not to OS (p=0.06). PLR level significantly affected both PFS (p<0.01) and OS (p=0.02). On multivariate analysis pre-treatment, SII level was significantly correlated to PFS (p=0.0079), but not to OS (p=0.15). We developed and externally validated on a cohort of 147 patients a logistic nomogram using SII, nodal status and pre-treatment Hb levels. Results showed a good predictive ability with C-index of 0.74. An online available calculator has also been developed. Conclusion: The low cost and easy profile in terms of determination and reproducibility make SII a promising tool for prognostic assessment in this oncological setting.
format Online
Article
Text
id pubmed-6506779
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65067792019-05-22 Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) Casadei-Gardini, Andrea Montagnani, Francesco Casadei, Chiara Arcadipane, Francesca Andrikou, Kalliopi Aloi, Deborah Prete, Alessandra Anna Zampino, Maria Giulia Argentiero, Antonella Pugliese, Giuseppe Martini, Stefania Iorio, Giuseppe Carlo Scartozzi, Mario Mistrangelo, Massimiliano Fornaro, Lorenzo Cassoni, Paola Marisi, Giorgia Dell’Acqua, Veronica Ravenda, Paola Simona Lonardi, Sara Silvestris, Nicola De Bari, Berardino Ricardi, Umberto Cascinu, Stefano Franco, Pierfrancesco Cancer Manag Res Original Research Background: In anal cancer, there are no markers nor other laboratory indexes that can predict prognosis and guide clinical practice for patients treated with concurrent chemoradiation. In this study, we retrospectively investigated the influence of immune inflammation indicators on treatment outcome of anal cancer patients undergoing concurrent chemoradiotherapy. Methods: All patients had a histologically proven diagnosis of squamous cell carcinoma of the anal canal/margin treated with chemoradiotherapy according to the Nigro’s regimen. Impact on prognosis of pre-treatment systemic index of inflammation (SII) (platelet x neutrophil/lymphocyte), neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were analyzed. Results: A total of 161 consecutive patients were available for the analysis. Response to treatment was the single most important factor for progression-free survival (PFS) and overall survival (OS). At univariate analysis, higher SII level was significantly correlated to lower PFS (p<0.01) and OS (p=0.046). NLR level was significantly correlated to PFS (p=0.05), but not to OS (p=0.06). PLR level significantly affected both PFS (p<0.01) and OS (p=0.02). On multivariate analysis pre-treatment, SII level was significantly correlated to PFS (p=0.0079), but not to OS (p=0.15). We developed and externally validated on a cohort of 147 patients a logistic nomogram using SII, nodal status and pre-treatment Hb levels. Results showed a good predictive ability with C-index of 0.74. An online available calculator has also been developed. Conclusion: The low cost and easy profile in terms of determination and reproducibility make SII a promising tool for prognostic assessment in this oncological setting. Dove 2019-04-26 /pmc/articles/PMC6506779/ /pubmed/31118786 http://dx.doi.org/10.2147/CMAR.S197349 Text en © 2019 Casadei-Gardini et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Casadei-Gardini, Andrea
Montagnani, Francesco
Casadei, Chiara
Arcadipane, Francesca
Andrikou, Kalliopi
Aloi, Deborah
Prete, Alessandra Anna
Zampino, Maria Giulia
Argentiero, Antonella
Pugliese, Giuseppe
Martini, Stefania
Iorio, Giuseppe Carlo
Scartozzi, Mario
Mistrangelo, Massimiliano
Fornaro, Lorenzo
Cassoni, Paola
Marisi, Giorgia
Dell’Acqua, Veronica
Ravenda, Paola Simona
Lonardi, Sara
Silvestris, Nicola
De Bari, Berardino
Ricardi, Umberto
Cascinu, Stefano
Franco, Pierfrancesco
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
title Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
title_full Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
title_fullStr Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
title_full_unstemmed Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
title_short Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
title_sort immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (arc: anal cancer response classifier)
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506779/
https://www.ncbi.nlm.nih.gov/pubmed/31118786
http://dx.doi.org/10.2147/CMAR.S197349
work_keys_str_mv AT casadeigardiniandrea immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT montagnanifrancesco immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT casadeichiara immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT arcadipanefrancesca immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT andrikoukalliopi immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT aloideborah immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT pretealessandraanna immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT zampinomariagiulia immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT argentieroantonella immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT pugliesegiuseppe immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT martinistefania immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT ioriogiuseppecarlo immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT scartozzimario immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT mistrangelomassimiliano immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT fornarolorenzo immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT cassonipaola immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT marisigiorgia immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT dellacquaveronica immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT ravendapaolasimona immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT lonardisara immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT silvestrisnicola immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT debariberardino immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT ricardiumberto immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT cascinustefano immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier
AT francopierfrancesco immuneinflammationindicatorsinanalcancerpatientstreatedwithconcurrentchemoradiationtrainingandvalidationcohortwithonlinecalculatorarcanalcancerresponseclassifier